Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)

被引：0
|
作者：
Mehta, J. [1 ]
Le-Ruyet, O. [2 ]
Fryzek, J. [3 ]
Iqbal, S. U. [1 ]
Mesa, R. [4 ]
机构：
[1] Sanofi Aventis, Evidence & Value Dev, Cambridge, MA USA
[2] Sanofi Aventis, Evidence & Value Dev, Chilly Mazarin, France
[3] Epidstat Inst, Ann Arbor, MI USA
[4] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1489
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [31] Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine
    Tashkandi, Hammad
    Younes, Ismail Elbaz
    CANCERS, 2024, 16 (09)
  • [32] Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia Vera (PV) and chronic idiopathic myelofibrosis (CIMF)
    Michiels, J. J.
    Bernema, Z.
    Van Bockstaele, D.
    De Raeve, H.
    Schroyens, W.
    PATHOLOGIE BIOLOGIE, 2007, 55 (02): : 92 - 104
  • [33] Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
    Ken Ogasawara
    Simon Zhou
    Gopal Krishna
    Maria Palmisano
    Yan Li
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 891 - 898
  • [34] The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ET-MF)
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Thomas, Deborah
    Cortes, Jorge
    Mesa, Ruben A.
    Hogan, William J.
    Redman, John R.
    Erickson-Viitanen, Sue
    Levy, Richard
    Vaddi, Kris
    Bradley, Edward
    Fridman, Jordan
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 622 - 622
  • [35] Nitric oxide and soluble plasma selectins in patients with essential thrombocythemia (et) and polycythemia vera (pv)
    Cella, G.
    Vianello, F.
    Marchetti, M.
    Vignoli, A.
    Panova, M.
    Barbui, T.
    Falanga, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 617 - 618
  • [36] The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 299 - 307
  • [37] A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
    Mascarenhas, John
    Wang, Xiaoli
    Rodriguez, Amelyn
    Xu, Mingjiang
    Gorman, Elaine
    Zhang, Wenyong
    Goldberg, Judith D.
    Najfeld, Vesna
    Hoffman, Ronald
    BLOOD, 2009, 114 (22) : 130 - 131
  • [38] Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
    Masarova, Lucia
    Alhuraiji, Ahmad
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Cortes, Jorge
    Pierce, Sherry
    Kantarjian, Hagop
    Verstovsek, Srdan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (03) : 257 - 263
  • [39] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [40] Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    T Barbui
    J Thiele
    A M Vannucchi
    A Tefferi
    Blood Cancer Journal, 2015, 5 : e337 - e337
12345